DNA repair pathways maintain the integrity of the genome and thereby help prevent the onset of cancer, disease and aging phenotypes. Further, many cancer treatments function by inducing genomic DNA damage. As such, the critical requirement for DNA repair proteins and pathways in response to radiation and genotoxic chemotherapeutics implicates DNA repair proteins as prime targets for improving response to currently available anti-cancer regimens. Essential to the development of specific DNA repair inhibitors is the availability of robust, highly sensitive assays to measure DNA repair capacity. In addition, defects in critical DNA repair pathways or proteins can predispose to cancer onset and may also provide an option for therapeutic selectivity. Many of these defects in the 150 or more DNA repair proteins can be detected using current "omics" technologies. However, there are many defects that can only be detected using functional assays such as those described herein. To effectively develop these tools, we suggest two specific aims:
Aim 1 will utilize a "Reverse Engineering" strategy as the basis for a novel discovery platform yielding the optimal dsDNA sequence for any DNA repair or DNA binding protein. This approach will allow DNA sequence dependence of individual DNA repair enzymes to influence probe (Molecular Beacon) optimization.
Aim 2 will exploit the optimized consensus sequence defined by the reverse engineering platform in Aim 1 for the development of highly selective and specific molecular beacon probes. To provide multiplexing capacity, we will optimize for multiple sets of fluor/quencher pairs and will evaluate each assay for use in 96-, 384- and 1536-well platforms to demonstrate high-throughput application.
In Aim 2, we will develop and optimize three user ready real-time fluorescence-based assays (DNA Repair Lights, DNA Repair PureLights and DNA Repair CaptureLights) amenable to DNA Repair quantification using purified proteins or cell and tissue lysates. The quantitative assays proposed here will provide a rapid, high-throughput method for the discovery and validation of DNA repair inhibitors and will be a valuable platform for functional DNA Repair measurements and biomarker analysis of cell/tumor lysates or tissue aspirates. We envision this as first in a series of assays towards the development of a complete DNA Repairomics platform.

Public Health Relevance

This Phase I proposal outlines a discovery Aim as a novel platform to optimize DNA sequence recognition for any DNA repair or DNA binding protein. This is followed by a second Aim describing three real-time fluorescence-based assays based on the optimized substrates discovered in Aim 1. We envision these DNA Repair Lights, DNA Repair PureLights and DNA Repair CaptureLights assays as the first in a series towards the development of a broad DNA Repairomics platform by the end of the Phase II project.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43ES025138-01A1
Application #
8646260
Study Section
Special Emphasis Panel (ZRG1-IMST-J (15))
Program Officer
Shaughnessy, Daniel
Project Start
2014-08-11
Project End
2015-01-31
Budget Start
2014-08-11
Budget End
2015-01-31
Support Year
1
Fiscal Year
2014
Total Cost
$202,050
Indirect Cost
Name
Trevigen, Inc.
Department
Type
DUNS #
807864772
City
Gaithersburg
State
MD
Country
United States
Zip Code
20877